The medication is applied across therapeutic domains where additional symptomatic support is needed. The drug is commonly applied in clinical settings that involve acute or unstable symptom patterns, such as influenza and ARVI, to help manage symptoms related to systemic imbalance. It also plays a role in conditions characterized by recurrent or episodic manifestations of inflammation and infection, including chronic bacterial prostatitis and chronic recurrent cystitis, as well as being used as an adjunct in complex cases like certain forms of pneumonia or purulent-inflammatory diseases.

The primary therapeutic purpose is to provide supportive relief during symptomatic periods. This approach means the medication supports the patient during difficult episodes by easing distress and assisting with maintaining functional stability.

Quick Fact: Relief for Heightened Symptoms

Area of Use	Primary Symptom Benefit	Clinical Context
Acute Infections	Helps manage discomfort related to fever and systemic imbalance.	Applied when symptoms intensify and supportive relief is needed.
Chronic Conditions	Relevant for managing symptoms that interfere with daily comfort.	Applicable within clinical settings involving recurrent inflammatory processes.
Recovery	Assists with maintaining functional stability.	Applied during phases of increased distress or discomfort (rehabilitation).

The regulatory profile for Галавит (Aminodihydrophthalasindione sodium) establishes clear rules for eligibility, defined primarily by age, reproductive status, and individual sensitivities. The medicine is classified as Contraindicated for specific populations.

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adult patients (18 years and older) are eligible for all forms. Adolescents (12 to 18 years) are eligible, as are children aged 6 to 11 years, though restricted to the injection and rectal suppository forms.

Populations for whom use is contraindicated: The medicine is absolutely prohibited for individuals with a known hypersensitivity to the active substance or any excipients. Use is also strictly prohibited during pregnancy and throughout the lactation (breastfeeding) period.

Age-related eligibility rules: Usage is contraindicated in children under 6 years for the injectable and suppository forms, and under 12 years for the sublingual tablets.

Condition-specific eligibility rules: The sublingual tablet form is contraindicated in patients with specific metabolic intolerances, including lactase deficiency or galactose/fructose intolerance, based on the excipient profile. No explicit contraindication for renal or hepatic impairment is listed in the official Contraindications section.

Pregnancy and lactation eligibility status (if explicitly documented): Contraindicated.

Connection to the Overall Eligibility Profile

Official documents define who can and cannot use this medicine by establishing absolute prohibitions based on reproductive status, minimum age thresholds for each pharmaceutical form, and patient-specific contraindications related to known intolerances.

The section on Interactions with other medicines and products for Галавит (Aminodihydrophthalasindione sodium) is structured based exclusively on the formal statements found in government regulatory drug labels. The interaction profile is characterized by one specific pharmacodynamic observation and a general absence of documented incompatibilities with co-administered substances.

Pharmacodynamic Interaction Profile

The only interaction consequence explicitly noted in official regulatory documentation involves the co-administration of Галавит with antibiotics. This combination is formally associated with a potential dose-sparing effect, which may permit a reduction in the overall course doses of the antibiotic when administered simultaneously. This is classified as a pharmacodynamic effect, although the underlying metabolic or transport mechanism is not formally specified in the label's interaction section. Official documents also confirm the medication's general compatibility, noting that cases of incompatibility with other broad classes of medicinal products, including antivirals and anti-inflammatory agents, are not documented.

Regulatory Constraints and Absence of Data

The formal interaction profile does not list any specific medicinal products that are contraindicated for co-administration. Furthermore, the documentation does not contain any mandatory timing separation requirements for administration. Regulatory sources also do not detail specific metabolic interactions involving cytochrome P450 (CYP) enzymes or drug transporters, nor do they specify interactions with food, alcohol, or herbal products. Population-specific interaction warnings—such as for patients with hepatic impairment or the elderly—are not noted in the official labeling.

How Галавит Works

Галавит (Aminodihydrophthalasindione sodium) functions as a mechanism-driven immunomodulator whose primary action is centered on regulating the activity of macrophages, which are key cellular drivers of both inflammatory and reparative processes.

---

Macrophage Modulation and Cytokine Control

The drug acts through reversible inhibition of the excessive synthesis and secretion of potent pro-inflammatory cytokines, specifically TNF-alpha and Interleukin-1 (IL-1), by hyperactivated macrophages. This molecular intervention moderates the systemic propagation of the inflammatory signal. The mechanism operates within systems characterized by heightened or dysregulated pathway signaling, which restricts the propagation of excessive mediator activity and contributes to the normalization of cytokine production kinetics.

---

Biphasic Action for Tissue Restoration

Beyond its inhibitory effects, the mechanism also enhances signaling for tissue restoration by stimulating macrophages to release growth factors. This secondary, biphasic action modulates cellular mechanisms that promote the resolution phase. This pathway engagement, driving cellular repair, contributes to the overall biphasic pharmacodynamic profile.

The administration of Galavit (aminodihydrophthalazinedione sodium) is governed by official instructions that specify the necessary procedural steps for correct and standardized use. Following these labeled guidelines ensures the medicine is delivered precisely according to the government-approved regimen.

Official Administration Directives

The instructions define the fundamental procedures for using the medicine:

• Route of Administration: The drug is typically administered via a specific route, such as intramuscular injection or sublingual (under the tongue) application, depending on the dosage form used in the treatment course.
• Dosing Regimen: The official protocol dictates the exact quantity of the drug for each dose and the required frequency (e.g., daily or every other day). The regimen is usually structured into an initial intensive phase followed by a maintenance phase over a set number of days.
• Preparation Steps: If the drug is supplied as a lyophilized powder, the official documentation specifies reconstitution—the required steps for dissolving the powder in an appropriate solvent (such as sterile water for injection) immediately prior to use.
• Treatment Course Duration: The labeled instructions explicitly define the total duration of the therapy, which may consist of a fixed number of injections or tablets, depending on the specific product and prescribed use.

Procedural Structure

The full course of administration is structured around these directives, establishing a clear sequence for patients and healthcare professionals. The instructions establish the mandatory timing and dosage. They ensure that the age-appropriate rules, when specified in regulatory documents, are strictly adhered to, and define the procedural response for a missed dose, if applicable, to maintain the required consistency of the drug’s use. The official instructions are the only approved source for defining the correct way to use the medicine.

Research Evidence / Overview of Studies for Галавит

---

Evidence for Use in Acute Respiratory Viral Infections (ARVI) and Influenza

Research evaluated the use of Галавит in studies exploring how symptoms change over time for acute respiratory viral infections (ARVI), including influenza. The evidence in this area included short-term randomized controlled trials (RCTs) and comparative studies, mainly involving adult patients with mild-to-moderate illness. These studies focused on outcomes related to physical discomfort and outcomes describing episodic or acute changes in condition. The findings describe patterns observed in the studies related to how symptoms evolved over the observation period, but the available data are often limited by their short-term nature, focusing only on the acute phase of the illness.

Evidence for Use in Chronic Bacterial Prostatitis and Recurrent Cystitis

Research examined the drug's role as an adjunct in research contexts involving fluctuating or unstable symptoms, such as chronic bacterial prostatitis and chronic recurrent cystitis. Studies included randomized prospective trials and clinical observations, evaluated in combination with established treatments like antibiotics. The studies applied in studies examining patient-reported experiences, tracking the frequency of recurrence or exacerbation and changes in validated scoring systems for discomfort. However, comparative evidence is lacking to isolate the full contribution of Галавит when used alone, and sample sizes were modest in many trials.

---

Research Gaps and What is Still Uncertain about Галавит

Data for Галавит are still emerging in several areas. Evidence quality varies across studies, with many of the findings originating from regional research, and systematic reviews from major international databases are still limited. Long-term effects are not fully established beyond the intermediate follow-up periods used in chronic condition studies. Furthermore, data for certain groups remain insufficient, as research primarily focuses on adult populations and has not been evaluated in specific populations such as children or pregnant women.

Key Studies & References

1. USING IMMUNOMODULATING DRUG GALAVIT IN TREATMENT OF INFLUENZA (Non-randomized comparative study)
2. Aminodihydrophthalazinedione Sodium Transdermal Therapeutic System Specific Activity on an Experimental Model of Extensive Liver Resection (Experimental Research)

Common questions about Галавит (FAQ)

Q: What is Галавит (Galavit)?

A: Галавит is the trade name for a medicinal product that contains the active substance aminodihydrophthalazinedione sodium, commonly referred to as Galavit in English-language scientific literature. This compound is typically used to support the immune system and has anti-inflammatory properties. It is often classified as an immunomodulator.

Q: How is Галавит administered?

A: Галавит is available in several forms, including:

• Rectal suppositories (usually 100 mg or 50 mg)
• Lyophilized powder for solution for intramuscular injection (typically 100 mg)

It is essential to follow the specific instructions and dosage regimen provided by a healthcare professional for the chosen form of administration.

Q: What are the main uses of Галавит?

A: Галавит is primarily used in the management of conditions associated with impaired immune function and inflammation. While its applications can vary, common uses include as an adjunct treatment for:

• Acute and chronic inflammatory diseases (e.g., infectious diseases, certain gynecological conditions).
• Immune deficiency states (e.g., certain viral infections).
• Post-operative care to support recovery.

Q: Are there any known side effects of Галавит?

A: Like all medications, Галавит may cause side effects, although not everyone experiences them. The most commonly reported side effect is an allergic reaction, such as itching, skin rash, or other hypersensitivity reactions. If you experience signs of a severe allergic reaction, such as swelling or difficulty breathing, seek immediate medical attention. It is always best to discuss potential side effects with a healthcare provider.

Q: Can pregnant or breastfeeding women use Галавит?

A: The use of Галавит during pregnancy and breastfeeding is generally contraindicated or not recommended due to limited or insufficient data on safety for the fetus or infant. A healthcare provider must carefully assess the potential risks versus benefits before considering its use in these populations.

Q: Who should not use Галавит?

A: Галавит is contraindicated in individuals with a known hypersensitivity or allergy to aminodihydrophthalazinedione sodium or any other component of the formulation. It is also generally not recommended for use in pregnant or breastfeeding women and children under the age of 6 (for the suppository form) or under the age of 18 (for the injection form), depending on the specific product instructions.

Q: How should Галавит be stored?

A: Галавит should be stored in a dry, dark place at a temperature not exceeding 25°C (77°F), unless otherwise specified on the packaging. Keep the medication out of the reach of children.

How to Store and Dispose of Галавит (Galavit)

Official labeling for Галавит (Aminodihydrophthalazinedione sodium) strictly defines the required storage environment to maintain product stability and shelf-life.

Storage Conditions

• Temperature: Rectal suppositories must be stored at a temperature not exceeding 25 C. The powder for injection requires storage between 15 C and 25 C.
• Environment and Protection: All forms must be stored in a dry place and be protected from light.
• Container and Safety: The medicine must remain in its original packaging and must be kept out of the sight and reach of children.
• Shelf-Life: The medicine has a labeled shelf-life of 3 years, but must not be used after the expiration date.

Handling and Disposal

The prepared solution for injection has no storage period and must be used immediately. Regarding disposal, the product must not be discarded into household waste or wastewater; unused or expired medication must be disposed of according to local pharmaceutical waste handling procedures.